Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Angiotensin 2 Receptor Blocker [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
LOSARTAN 21,916 2,034 9.3% 7,032 1,175 65.2 yrs 59.8%
VALSARTAN 21,720 1,696 7.8% 7,746 1,294 67.1 yrs 58.1%
OLMESARTAN MEDOXOMIL 11,972 283 2.4% 6,564 316 66.9 yrs 56.6%
IRBESARTAN 10,144 636 6.3% 5,374 1,060 69.0 yrs 60.2%
TELMISARTAN 5,953 599 10.1% 2,440 371 67.9 yrs 58.9%
CANDESARTAN CILEXETIL 5,928 484 8.2% 2,921 701 67.9 yrs 60.3%
SPARSENTAN 3,280 18 0.5% 209 2 49.3 yrs 43.8%
AZILSARTAN KAMEDOXOMIL 1,000 52 5.2% 199 29 67.5 yrs 52.6%

Head-to-Head Comparisons

LOSARTAN vs VALSARTAN LOSARTAN vs OLMESARTAN MEDOXOMIL LOSARTAN vs IRBESARTAN LOSARTAN vs TELMISARTAN VALSARTAN vs OLMESARTAN MEDOXOMIL VALSARTAN vs IRBESARTAN VALSARTAN vs TELMISARTAN OLMESARTAN MEDOXOMIL vs IRBESARTAN OLMESARTAN MEDOXOMIL vs TELMISARTAN IRBESARTAN vs TELMISARTAN
← Back to Angiotensin 2 Receptor Blocker [EPC] Class side effects →